The "ComPAS Trial" combined treatment model for acute malnutrition: study protocol for the economic evaluation

Trials

Lani Trenouth¹  Chloe Puett¹  Dieynaba S. N’Diaye²  Jeanette Bailey³  Hassan Haghparast-Bidgoli⁴  Amy Mayberry⁵  Natasha Lelijveld⁵ 

[1] Action Against Hunger USA;Action Contre la Faim (ACF);Department of Population Health, London School of Hygiene and Tropical Medicine;Institute for Global Health, University College London;No Wasted Lives, Action Against Hunger UK;

关键词: Cost-effectiveness;    Severe acute malnutrition;    Moderate acute malnutrition;    Community management of acute malnutrition;    Cost-consequence analysis;   

DOI  :  10.1186/s13063-018-2594-7

来源: DOAJ

【 摘 要 】

Abstract Background Acute malnutrition is currently divided into severe (SAM) and moderate (MAM) based on level of wasting. SAM and MAM currently have separate treatment protocols and products, managed by separate international agencies. For SAM, the dose of treatment is allocated by the child’s weight. A combined and simplified protocol for SAM and MAM, with a standardised dose of ready-to-use therapeutic food (RUTF), is being trialled for non-inferior recovery rates and may be more cost-effective than the current standard protocols for treating SAM and MAM. Method This is the protocol for the economic evaluation of the ComPAS trial, a cluster-randomised controlled, non-inferiority trial that compares a novel combined protocol for treating uncomplicated acute malnutrition compared to the current standard protocol in South Sudan and Kenya. We will calculate the total economic costs of both protocols from a societal perspective, using accounting data, interviews and survey questionnaires. The incremental cost of implementing the combined protocol will be estimated, and all costs and outcomes will be presented as a cost-consequence analysis. Incremental cost-effectiveness ratio will be calculated for primary and secondary outcome, if statistically significant. Discussion We hypothesise that implementing the combined protocol will be cost-effective due to streamlined logistics at clinic level, reduced length of treatment, especially for MAM, and reduced dosages of RUTF. The findings of this economic evaluation will be important for policymakers, especially given the hypothesised non-inferiority of the main health outcomes. The publication of this protocol aims to improve rigour of conduct and transparency of data collection and analysis. It is also intended to promote inclusion of economic evaluation in other nutrition intervention studies, especially for MAM, and improve comparability with other studies. Trial Registration ISRCTN 30393230, date: 16/03/2017.

【 授权许可】

Unknown